Drugs / SerpinPC
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04073498 | Aug 2019 → Sep 2024 | hemophilia A, hemophilia B | ApcinteX Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05789537 | Jul 2023 → Nov 2024 | hemophilia B | ApcinteX Ltd | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05789524 | Jul 2023 → Nov 2024 | hemophilia A, hemophilia B | ApcinteX Ltd | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT06568302 | Jul 2024 → Jan 2025 | hemophilia A, hemophilia B | ApcinteX Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SerpinPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06568302 ↗ |
| Action | Inhibit | “Activated Protein C (APC) inhibitor” NCT05789524 ↗ |
| Route | Intravenous | “Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.” NCT04073498 ↗ |
| Route | Subcutaneous | “Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.” NCT04073498 ↗ |